“Last conference call Nader speculated that a buy out
“Last conference call Nader speculated that a buy out would be difficult but would be way more than IMMU. He stated that he sees a buy out by indications.”
NP speculates in many topics and 75% of that speculation never materializes. IMMU has an FDA approved drug for breast cancer, CYDY is still trying to finalize the HIV combo BLA. At this point in time, CYDY is not with anywhere near what IMMU is.
“Once one is approved and the safety is addressed then the other indications can use that same safety record and do small phase 2 trials for proof of concept and quick phase 3 trials to prove efficacy in that indication.”
Very few phase 3 trials are quick and neither are phase 2s. The problem with CYDY is speed of enrollment. The NASH trial is 90 patients for 14 weeks and the estimated completion date is March of 2022.
IMO, there is nothing wrong with taking a nice profit now vs assuming risk in the future. There is no guarantee that leronlimab will work in all of these indications. Yes, the preclinical studies are great but that doesn’t always equate to results. The mTNBC trial results don’t appear to be as good as we expected as NP has been very hush about the topic. He has not discussed results, has not mentioned the BTD application and said in a recent CC about the trial that, “there isn’t a clear signal.” This doesn’t mean the trial has failed, but it isn’t what we expected.
3
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
The Role of Catalysts in Modern Industry Swing by any bustling industrial hub, and you're likely to catch talk about catalysts—unsung heroes that make the machinery of modern industry run smoother, faster, and cleaner. Over in Tianjin, China, Sinopec just wrapped up its Second International Catalyst Customer Conference, which is less of a tongue-twister than it sounds....
Continue Reading
Tech-Savvy Elegance at Canton Fair Dive into the glitz and glamour of the jewelry zone at the 140th Canton Fair, where technology and craftsmanship are forging a new narrative for luxury accessories. This isn’t just your grandmother’s jewelry box we're talking about anymore. We’re witnessing the dawn of precious metal smart rings and dual-band smart watches that...
Continue Reading
Flagstar's Descent: What Led to the Stock Tumble? And here we go again with a big name in finance taking a hit right between the eyes. Flagstar Bank, under ticker NYSE:FLG, saw its shares plummet by over 9.2% on October 23, 2026. This isn't just a blip—it's a spill. The backdrop here is an eye-watering $12.9 billion loan book tied to rent-regulated apartment buildings....
Continue Reading
Nucor's Solid Third Quarter Performance Nucor Corporation is flexing its muscles, reporting a robust third quarter for 2026. With net earnings hitting $1.32 billion and a diluted earnings per share of $5.80, the steel giant has shown it can more than hold its ground in a competitive market. Compare that to last quarter's $1.16 billion - we're seeing serious momentum....
Continue Reading
A Celebration of Science and Heritage In an era where institutions are either scaling back or going digital, Florida Southern College is doubling down on its roots and looking skyward. On October 22, 2026, the campus buzzed with a celebration that would have done any investor in education and heritage proud—raising the Ben and Missy Albritton Citrus and Horticulture...
Continue Reading
Why a Trade Fair Needs Lion Dances October 2026 marks a time when talking about a trade fair means diving headfirst into a whirlpool of global exchange and cultural tango we don’t often see in the West. Yeah, I'm looking at you, Canton Fair—a long-runner over in China that's managed to haul in the globe to not just showcase wares, but bring people together in a clash...
Continue Reading
Innventure’s Market Tumult: Unraveling the Drama Talk about a mess. Innventure Inc. (NASDAQ: INV) investors are likely feeling a sting sharper than a bee that's lost its hive after a painful 55% stock crash back in August 2026. The culprit? A scuttled project involving a shadowy partner, DarkNX, and a lot of questions about who knew what and when. A Puzzling...
Continue Reading
Essential Oils: Aromatherapy's New Frontier and Pharma Ally What’s the deal with essential oils? Well, it seems they’re not just for your neighbor’s pricey diffuser anymore. According to some fresh numbers, we're staring down a market worth nearly $30 billion by 2031. And it ain't all incense and hippie stores fueling this beast — we're talking a serious expansion...
Continue Reading
Spotting Trouble Beneath the Surface Now, when was the last time you eyeballed your home’s plumbing with more than a passing glance? Most folks don’t give their sewer lines two thoughts until something foul pops up. Plumbing expert Jessica Gerdeman from Heggemann, Inc. in Warrenton, Missouri, isn’t just blowing hot air when she points out the indicators of looming...
Continue Reading
A Firm's Gratitude with a Dash of Holiday Cheer It takes more than just legal prowess to make waves in a community. Tyler Mann Injury Law is stepping outside the courtroom to bring some warmth to Alabama families this Thanksgiving. They're hosting a giveaway that puts a little financial relief where it counts—at the Thanksgiving dinner table, straightening out the...
Continue Reading
Top 5 Most Recently Viewed Articles
Welcoming Dr. Chitra Rajagopal to the Oncology Team American Oncology Network (AON), known for its rapid growth in community-based oncology practices, proudly announces the addition of Dr. Chitra Rajagopal, an esteemed medical oncologist. Her presence enhances the physician care team at The Center for Cancer and Blood Disorders, where she will be treating patients in the...
Continue Reading
Earnings Forecast for Rapid Micro Biosystems Rapid Micro Biosystems (NASDAQ: RPID) is poised to reveal its quarterly earnings soon. Investors are eager to see if the company can meet or exceed analyst expectations, particularly as they await the announcement regarding an estimated earnings per share (EPS) of $-0.26. This figure serves as a benchmark, providing insight...
Continue Reading
Understanding Recent Options Activity of AppLovin In the world of stocks and investments, intriguing signals often emerge, especially when deep-pocketed investors begin to take interest. Recently, AppLovin (NASDAQ: APP) has captured the attention of many with its unusual options activity, hinting at potential market movements that traders shouldn't overlook. A Surge in...
Continue Reading
Empowering Youth Against Corruption: ICAC's Landmark Program The Hong Kong International Academy Against Corruption, in collaboration with key international partners, has successfully launched the first-ever regional capacity building program focused on engaging youth in anti-corruption efforts. This initiative is crucial for fostering a culture of integrity among young...
Continue Reading
Innovaderm Research Expands into Rheumatology Innovaderm Research, recognized for its expertise in dermatology, is thrilled to announce an important new addition to its team. Dr. Juan Gabriel Ovalles Bonilla, MD, PhD, an accomplished and board-certified rheumatologist, will be joining Innovaderm. His extensive experience brings added strength to the company’s efforts...
Continue Reading